Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Buy" by Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has earned a consensus rating of "Buy" from the ten ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $20.89.

YMAB has been the topic of several recent analyst reports. Oppenheimer began coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an "outperform" rating and a $23.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a "buy" rating and a $17.00 target price for the company. Finally, Wedbush reaffirmed an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday.

Y-mAbs Therapeutics Stock Down 7.7 %

YMAB stock traded down $0.40 during midday trading on Friday, reaching $4.79. The company's stock had a trading volume of 386,247 shares, compared to its average volume of 467,664. The business's 50-day simple moving average is $6.52 and its 200-day simple moving average is $10.67. The stock has a market cap of $214.54 million, a PE ratio of -8.89 and a beta of 0.67. Y-mAbs Therapeutics has a 52 week low of $4.25 and a 52 week high of $18.19.

Remove Ads

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period last year, the business earned ($0.02) EPS. As a group, equities analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. increased its holdings in shares of Y-mAbs Therapeutics by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after buying an additional 1,903 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Y-mAbs Therapeutics by 12.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company's stock valued at $179,000 after buying an additional 2,545 shares during the period. JPMorgan Chase & Co. lifted its stake in Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock valued at $399,000 after buying an additional 2,854 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth about $44,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock valued at $113,000 after purchasing an additional 3,416 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.